

# Raymond C Vanholder

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8441717/publications.pdf>

Version: 2024-02-01

569  
papers

39,822  
citations

2203

99  
h-index

4203

174  
g-index

583  
all docs

583  
docs citations

583  
times ranked

27295  
citing authors

#	ARTICLE	IF	CITATIONS
1	The European Green Deal and nephrology: a call for action by the European Kidney Health Alliance. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 1080-1088.	0.4	21
2	The European Kidney Health Alliance (EKHA) and the Decade of the Kidney™. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 1113-1122.	0.4	7
3	Patient-reported factors influencing the choice of their kidney replacement treatment modality. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 477-488.	0.4	18
4	Uremic encephalopathy. <i>Kidney International</i> , 2022, 101, 227-241.	2.6	19
5	What If Not All Metabolites from the Uremic Toxin Generating Pathways Are Toxic? A Hypothesis. <i>Toxins</i> , 2022, 14, 221.	1.5	20
6	Future Directions for Dialysis. <i>Kidney and Dialysis</i> , 2022, 2, 153-162.	0.5	1
7	Continuing kidney care in conflicts. <i>Nature Reviews Nephrology</i> , 2022, 18, 479-480.	4.1	18
8	Mass Disasters and Burnout in Nephrology Personnel. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 829-837.	2.2	19
9	Health literacy problems of kidney patients. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1155-1157.	0.4	1
10	A history of uremic toxicity and of the European Uremic Toxin Work Group (EUTox). <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1514-1523.	1.4	8
11	EDTAKI: a Nephrology and Public Policy Committee platform call for more European involvement in acute kidney injury. <i>Nephrology Dialysis Transplantation</i> , 2021, , .	0.4	4
12	Fighting the unbearable lightness of neglecting kidney health: the decade of the kidney. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1719-1730.	1.4	41
13	Data Sharing Under the General Data Protection Regulation. <i>Hypertension</i> , 2021, 77, 1029-1035.	1.3	47
14	Kidney problems in disaster situations. <i>Nephrologie Et Therapeutique</i> , 2021, 17, S27-S36.	0.2	6
15	Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations. <i>Nature Reviews Nephrology</i> , 2021, 17, 528-542.	4.1	70
16	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Western Europe. <i>Kidney International Supplements</i> , 2021, 11, e106-e118.	4.6	29
17	Organ donation and transplantation: a multi-stakeholder call to action. <i>Nature Reviews Nephrology</i> , 2021, 17, 554-568.	4.1	89
18	Expanding Utilization of Home Dialysis: An Action Agenda From the First International Home Dialysis Roundtable. <i>Kidney Medicine</i> , 2021, 3, 635-643.	1.0	22

#	ARTICLE	IF	CITATIONS
19	Classification of Uremic Toxins and Their Role in Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1918-1928.	2.2	74
20	Supplemented ERA-EDTA Registry data evaluated the frequency of dialysis, kidney transplantation, and comprehensive conservative management for patients with kidney failure in Europe. <i>Kidney International</i> , 2021, 100, 182-195.	2.6	31
21	Urinary proteomics combined with home blood pressure telemonitoring for health care reform trial: rationale and protocol. <i>Blood Pressure</i> , 2021, 30, 269-281.	0.7	8
22	Uremic Toxins and Cardiovascular System. <i>Cardiology Clinics</i> , 2021, 39, 307-318.	0.9	7
23	Measured Glomerular Filtration Rate: The Query for a Workable Golden Standard Technique. <i>Journal of Personalized Medicine</i> , 2021, 11, 949.	1.1	13
24	Syndecan-1 and Free Indoxyl Sulfate Levels Are Associated with miR-126 in Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10549.	1.8	11
25	Results of the European EDITH nephrologist survey on factors influencing treatment modality choice for end-stage kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, 126-138.	0.4	11
26	Free <i>c</i> -resyl sulfate shows the highest association with cardiovascular outcome in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 998-1005.	0.4	32
27	A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 23-35.	1.4	10
28	COVID-19 and policy changes for kidney disease: the need for a "decade of the kidney". <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 8-11.	0.4	3
29	Single needle hemodialysis: is the past the future?. <i>Journal of Nephrology</i> , 2020, 33, 49-58.	0.9	5
30	Disasters, children and the kidneys. <i>Pediatric Nephrology</i> , 2020, 35, 1381-1393.	0.9	21
31	Identifying critically important vascular access outcomes for trials in haemodialysis: an international survey with patients, caregivers and health professionals. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 657-668.	0.4	22
32	Haemodiafiltration does not lower protein-bound uraemic toxin levels compared with haemodialysis in a paediatric population. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 648-656.	0.4	14
33	Low hemoglobin at hemodialysis initiation: an international study of anemia management and mortality in the early dialysis period. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 425-433.	1.4	12
34	Moving ahead on the Kidney Health Initiative innovation roadmap, a transatlantic progress update. <i>Artificial Organs</i> , 2020, 44, 1125-1134.	1.0	3
35	Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>Kidney Medicine</i> , 2020, 2, 286-296.	1.0	21
36	Role of the International and National Renal Organizations in Natural Disasters: Strategies for Renal Rescue. <i>Seminars in Nephrology</i> , 2020, 40, 393-407.	0.6	13

#	ARTICLE	IF	CITATIONS
37	The current and future landscape of dialysis. <i>Nature Reviews Nephrology</i> , 2020, 16, 573-585.	4.1	252
38	Acute Kidney Injury in Active Wars and Other Man-Made Disasters. <i>Seminars in Nephrology</i> , 2020, 40, 341-353.	0.6	17
39	The authors reply. <i>Kidney International</i> , 2020, 98, 784.	2.6	0
40	Funding kidney research as a public health priority: challenges and opportunities. <i>Nephrology Dialysis Transplantation</i> , 2020, , .	0.4	6
41	Difference in Profiles of the Gut-Derived Tryptophan Metabolite Indole Acetic Acid between Transplanted and Non-Transplanted Patients with Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2031.	1.8	17
42	Health Policy for Dialysis Care in Canada and the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1669-1677.	2.2	6
43	Ethical challenges in nephrology: a call for action. <i>Nature Reviews Nephrology</i> , 2020, 16, 603-613.	4.1	26
44	Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease. <i>Kidney International</i> , 2020, 97, 1230-1242.	2.6	125
45	&lt;p&gt;Estimating the Fraction of First-Year Hemodialysis Deaths Attributable to Potentially Modifiable Risk Factors: Results from the DOPPS&lt;p&gt;. <i>Clinical Epidemiology</i> , 2020, Volume 12, 51-60.	1.5	10
46	A call for harmonization of European kidney care: dialysis reimbursement and distribution of kidney replacement therapies. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 979-986.	0.4	16
47	FO079CONCENTRATIONS OF P-CRESYL - AND INDOXYL SULFATE AND THEIR PRECURSORS IN DIFFERENT STAGES OF CHRONIC KIDNEY DISEASE: FROM FECES TO URINE. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
48	Contribution of the uremic milieu to an increased pro-inflammatory monocytic phenotype in chronic kidney disease. <i>Scientific Reports</i> , 2019, 9, 10236.	1.6	21
49	SP682THE IMPACT OF DIALYSIS MODALITIES AND REIMBURSEMENT FEES ON PUBLIC HEALTH CARE EXPENDITURE IN EUROPEAN COUNTRIES WITH HIGHER AND LOWER GDPc. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
50	Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1469-1480.	0.4	8
51	The new European Renal Best Practice guideline on arteriovenous access: why worthwhile to read. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1071-1074.	0.4	1
52	Clinical practice guideline on peri- and postoperative care of arteriovenous fistulas and grafts for haemodialysis in adults. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, ii1-ii42.	0.4	94
53	A swan song for Kt/V<sub>urea</sub>. <i>Seminars in Dialysis</i> , 2019, 32, 424-437.	0.7	26
54	Uremic Toxin Concentrations are Related to Residual Kidney Function in the Pediatric Hemodialysis Population. <i>Toxins</i> , 2019, 11, 235.	1.5	20

#	ARTICLE	IF	CITATIONS
55	Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients. <i>Scientific Reports</i> , 2019, 9, 4477.	1.6	62
56	Evolution of protein-bound uremic toxins indoxyl sulphate and p-cresyl sulphate in acute kidney injury. <i>International Urology and Nephrology</i> , 2019, 51, 293-302.	0.6	25
57	Gut microbiota dynamics and uraemic toxins: one size does not fit all. <i>Gut</i> , 2019, 68, 2257.1-2260.	6.1	37
58	How to increase kidney transplant activity throughout Europe – an advocacy review by the European Kidney Health Alliance. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1254-1261.	0.4	24
59	An International Analysis of Dialysis Services Reimbursement. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 84-93.	2.2	71
60	Subclinical AKI: ready for primetime in clinical practice?. <i>Journal of Nephrology</i> , 2019, 32, 9-16.	0.9	29
61	Outcomes of Intermittent Hemodialysis in Critically Ill Patients With Acute Kidney Injury. , 2019, , 960-966.e3.		1
62	Report of the Standardized Outcomes in Nephrology – Hemodialysis (SONG-HD) Consensus Workshop on Establishing a Core Outcome Measure for Hemodialysis Vascular Access. <i>American Journal of Kidney Diseases</i> , 2018, 71, 690-700.	2.1	62
63	Haste makes waste – Should current guideline recommendations for initiation of renal replacement therapy for acute kidney injury be changed?. <i>Seminars in Dialysis</i> , 2018, 31, 204-208.	0.7	7
64	Diagnosis and management of asymptomatic bacteriuria in kidney transplant recipients: a survey of current practice in Europe. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1661-1668.	0.4	32
65	Caring for Migrants and Refugees With End-Stage Kidney Disease in Europe. <i>American Journal of Kidney Diseases</i> , 2018, 71, 701-709.	2.1	26
66	European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 563-573.	0.4	28
67	A plea for more uremic toxin research in children with chronic kidney disease. <i>Pediatric Nephrology</i> , 2018, 33, 921-924.	0.9	8
68	Increased urinary osmolyte excretion indicates chronic kidney disease severity and progression rate. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 2156-2164.	0.4	46
69	Urea and chronic kidney disease: the comeback of the century? (in uraemia research). <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 4-12.	0.4	122
70	Early and asymptomatic cardiac dysfunction in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 450-458.	0.4	21
71	Mortality risk in patients on hemodiafiltration versus hemodialysis: a “real-world” comparison from the DOPPS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 683-689.	0.4	69
72	Accumulation of uraemic toxins is reflected only partially by estimated GFR in paediatric patients with chronic kidney disease. <i>Pediatric Nephrology</i> , 2018, 33, 315-323.	0.9	15

#	ARTICLE	IF	CITATIONS
73	Vascular Access Outcomes Reported in Maintenance Hemodialysis Trials: A Systematic Review. American Journal of Kidney Diseases, 2018, 71, 382-391.	2.1	41
74	Points of Concern in Post Acute Kidney Injury Management. Nephron, 2018, 138, 92-103.	0.9	21
75	Introduction to the Toxins Special Issue on "Novel Issues in Uremic Toxicity". Toxins, 2018, 10, 388.	1.5	5
76	Association between Protein-Bound Uremic Toxins and Asymptomatic Cardiac Dysfunction in Patients with Chronic Kidney Disease. Toxins, 2018, 10, 520.	1.5	21
77	Lipid management in patients with chronic kidney disease. Nature Reviews Nephrology, 2018, 14, 727-749.	4.1	153
78	SP340 IS LOW HEMOGLOBIN AT HEMODIALYSIS INITIATION ASSOCIATED WITH FIRST-YEAR SURVIVAL AMONG PATIENTS TREATED TO TARGET LEVELS SOON AFTER DIALYSIS START?. Nephrology Dialysis Transplantation, 2018, 33, i459-i459.	0.4	0
79	FP318 IMPACT OF THE METRIC USED TO DEFINE PROGRESSION OF KIDNEY FAILURE ON THE CONCLUSIONS OF STUDIES. Nephrology Dialysis Transplantation, 2018, 33, i138-i138.	0.4	0
80	Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update. Toxins, 2018, 10, 33.	1.5	218
81	Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). Toxins, 2018, 10, 237.	1.5	28
82	Association between serum ferritin and mortality: findings from the USA, Japan and European Dialysis Outcomes and Practice Patterns Study. Nephrology Dialysis Transplantation, 2018, 33, 2234-2244.	0.4	57
83	Gut-Derived Metabolites and Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1311-1313.	2.2	6
84	Disaster medicine and response: Optimizing life-saving potential. American Journal of Disaster Medicine, 2018, 13, 253-264.	0.1	12
85	Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. Nephrology Dialysis Transplantation, 2017, 32, gfw337.	0.4	62
86	Association between changes in quality of life and mortality in hemodialysis patients: results from the DOPPS. Nephrology Dialysis Transplantation, 2017, 32, gfw233.	0.4	42
87	Epidemiology of acute kidney injury in children worldwide, including developing countries. Pediatric Nephrology, 2017, 32, 1301-1314.	0.9	44
88	Chronic kidney disease. Clinical Science, 2017, 131, 225-226.	1.8	16
89	Metabolic profiling of human plasma and urine in chronic kidney disease by hydrophilic interaction liquid chromatography coupled with time-of-flight mass spectrometry: a pilot study. Analytical and Bioanalytical Chemistry, 2017, 409, 2201-2211.	1.9	32
90	Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association "European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)*. Nephrology Dialysis Transplantation, 2017, 32, 620-640.	0.4	133

#	ARTICLE	IF	CITATIONS
91	The systemic nature of CKD. <i>Nature Reviews Nephrology</i> , 2017, 13, 344-358.	4.1	265
92	Hypertension in dialysis patients. <i>Journal of Hypertension</i> , 2017, 35, 657-676.	0.3	56
93	Guía de práctica clínica sobre el diagnóstico y tratamiento de la hiponatremia. <i>Nefrología</i> , 2017, 37, 370-380.	0.2	15
94	Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. <i>Nature Reviews Nephrology</i> , 2017, 13, 393-409.	4.1	200
95	Type 2 diabetes: a two-headed snake in kidney transplant recipients?. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 3-5.	5.5	2
96	Further approaches to reduce the cost of renal replacement therapy. <i>Nature Reviews Nephrology</i> , 2017, 13, 720-720.	4.1	2
97	Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. <i>Kidney International Reports</i> , 2017, 2, 1066-1075.	0.4	77
98	p-Cresyl glucuronide is a major metabolite of p-cresol in mouse: in contrast to p-cresyl sulphate, p-cresyl glucuronide fails to promote insulin resistance. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 2000-2009.	0.4	24
99	SP777 TAILORED IMMUNOSUPPRESSION IN DE NOVO RENAL TRANSPLANTATION BASED ON IMMUNE FUNCTION MONITORING: A RANDOMISED CONTROLLED TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, iii406-iii406.	0.4	0
100	p-Cresyl Sulfate. <i>Toxins</i> , 2017, 9, 52.	1.5	262
101	Uremic Toxin Section in the Journal <i>Toxins</i> : A Powerful Tool to Bundle and Advance Knowledge on Uremia. <i>Toxins</i> , 2017, 9, 170.	1.5	1
102	Effect of Magnesium Supplements on Insulin Secretion After Kidney Transplantation: A Randomized Controlled Trial. <i>Annals of Transplantation</i> , 2017, 22, 524-531.	0.5	17
103	Spontaneous variability of pre-dialysis concentrations of uremic toxins over time in stable hemodialysis patients. <i>PLoS ONE</i> , 2017, 12, e0186010.	1.1	25
104	Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS versus ELISA. <i>Toxins</i> , 2016, 8, 149.	1.5	26
105	Response to Tsikas et al. Comments on Boelaert et al. Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS versus ELISA. <i>Toxins</i> 2016, 8, 149. <i>Toxins</i> , 2016, 8, 312.	1.5	0
106	Protein-Bound Uremic Toxin Profiling as a Tool to Optimize Hemodialysis. <i>PLoS ONE</i> , 2016, 11, e0147159.	1.1	45
107	Renal replacement therapy for refugees with end-stage kidney disease: an international survey of the nephrological community. <i>Kidney International Supplements</i> , 2016, 6, 35-41.	4.6	31
108	Clinical management of the uraemic syndrome in chronic kidney disease. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 360-373.	5.5	78

#	ARTICLE	IF	CITATIONS
109	Intestinal metabolites, chronic kidney disease and renal transplantation: Enigma Variations?. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1547-1551.	0.4	11
110	Hypertension in Chronic Kidney Disease Part 1. <i>Hypertension</i> , 2016, 67, 1093-1101.	1.3	63
111	Hypertension in Chronic Kidney Disease Part 2. <i>Hypertension</i> , 2016, 67, 1102-1110.	1.3	86
112	Long-term outcome in ICU patients with acute kidney injury treated with renal replacement therapy: a prospective cohort study. <i>Critical Care</i> , 2016, 20, 256.	2.5	94
113	Development of a MALDI MS-based platform for early detection of acute kidney injury. <i>Proteomics - Clinical Applications</i> , 2016, 10, 732-742.	0.8	13
114	Acute kidney injury in critically ill cancer patients: an update. <i>Critical Care</i> , 2016, 20, 209.	2.5	64
115	Levels of Indoxyl Sulfate in Kidney Transplant Patients, and the Relationship With Hard Outcomes. <i>Circulation Journal</i> , 2016, 80, 722-730.	0.7	28
116	New low-flux mixed matrix membranes that offer superior removal of protein-bound toxins from human plasma. <i>Scientific Reports</i> , 2016, 6, 34429.	1.6	58
117	Statins for the prevention of contrast-induced acute kidney injury. <i>Current Opinion in Nephrology and Hypertension</i> , 2016, 25, 508-517.	1.0	6
118	HEMO Revisited: Why Kt/Vurea Only Tells Part of the Story. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3235-3237.	3.0	11
119	The cell cycle biomarkers: promising research, but do not oversell them. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 353-358.	1.4	32
120	Urinary myeloid IgA Fc alpha receptor (CD89) and transglutaminase-2 as new biomarkers for active IgA nephropathy and henoch-Schönlein purpura nephritis. <i>BBA Clinical</i> , 2016, 5, 79-84.	4.1	24
121	Magnesium and infection risk after kidney transplantation: An observational cohort study. <i>Journal of Infection</i> , 2016, 73, 8-17.	1.7	11
122	Bisphosphonates for preventing bone disease in kidney transplant recipients: a meta-analysis of randomized controlled trials. <i>Transplant International</i> , 2016, 29, 153-164.	0.8	8
123	Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 337-348.	0.4	206
124	Does pre-emptive transplantation versus post start of dialysis transplantation with a kidney from a living donor improve outcomes after transplantation? A systematic literature review and position statement by the Descartes Working Group and ERBP. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 691-697.	0.4	62
125	Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target. <i>American Journal of Kidney Diseases</i> , 2016, 67, 483-498.	2.1	271
126	Future Avenues to Decrease Uremic Toxin Concentration. <i>American Journal of Kidney Diseases</i> , 2016, 67, 664-676.	2.1	72

#	ARTICLE	IF	CITATIONS
127	Cost of renal replacement: how to help as many as possible while keeping expenses reasonable?. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1251-1261.	0.4	42
128	Association of advanced age with concentrations of uraemic toxins in CKD. <i>Journal of Nephrology</i> , 2016, 29, 81-91.	0.9	10
129	Long-term quality of life in critically ill patients with acute kidney injury treated with renal replacement therapy: a matched cohort study. <i>Critical Care</i> , 2015, 19, 289.	2.5	34
130	Chronic Kidney Disease and Fibrosis: The Role of Uremic Retention Solutes. <i>Frontiers in Medicine</i> , 2015, 2, 60.	1.2	52
131	Where and When To Inject Low Molecular Weight Heparin in Hemodiafiltration? A Cross Over Randomised Trial. <i>PLoS ONE</i> , 2015, 10, e0128634.	1.1	18
132	FP279HIGH-RESOLUTION PLASMA PROTEOME ANALYSIS IDENTIFIES NEW CHANGES IN MOLECULAR MECHANISMS INVOLVED IN CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii160-iii161.	0.4	1
133	Once upon a time in dialysis: the last days of Kt/V?. <i>Kidney International</i> , 2015, 88, 460-465.	2.6	67
134	Disaster nephrology: a new concept for an old problem. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 300-309.	1.4	46
135	A survey on the methodological processes and policies of renal guideline groups as a first step to harmonize renal guidelines. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1066-1074.	0.4	8
136	The fate of triaged and rejected manuscripts. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1947-1950.	0.4	9
137	Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1028-1037.	0.4	81
138	Pro-inflammatory cytokines and leukocyte oxidative burst in chronic kidney disease: culprits or innocent bystanders?. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 943-951.	0.4	25
139	Comparison of different equations to assess glomerular filtration in critically ill patients. <i>Intensive Care Medicine</i> , 2015, 41, 427-435.	3.9	98
140	Proteomic biomarkers in kidney disease: issues in development and implementation. <i>Nature Reviews Nephrology</i> , 2015, 11, 221-232.	4.1	101
141	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1999-2010.	3.0	205
142	Chronic kidney disease progression is mainly associated with non-recovery of acute kidney injury. <i>Journal of Nephrology</i> , 2015, 28, 709-716.	0.9	26
143	New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1842-1852.	0.4	64
144	Protein-bound uraemic toxins, dicarbonyl stress and advanced glycation end products in conventional and extended haemodialysis and haemodiafiltration. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1395-1402.	0.4	52

#	ARTICLE	IF	CITATIONS
145	The intestine and the kidneys: a bad marriage can be hazardous. CKJ: Clinical Kidney Journal, 2015, 8, 168-179.	1.4	82
146	International Society of Nephrology's Oby25 initiative for acute kidney injury (zero preventable deaths) Tj ETQq0 0 0 rgBT /Overlock 10 T	8.3	780
147	Crush Syndrome: A Case Report and Review of the Literature. Journal of Emergency Medicine, 2015, 48, 730-731.	0.3	6
148	Validity of Vascular Calcification as a Screening Tool and as a Surrogate End Point in Clinical Research. Hypertension, 2015, 66, 3-9.	1.3	23
149	The double challenge of resistant hypertension and chronic kidney disease. Lancet, The, 2015, 386, 1588-1598.	6.3	147
150	Removal of Different Classes of Uremic Toxins in APD vs CAPD: A Randomized Cross-Over Study. Peritoneal Dialysis International, 2015, 35, 436-442.	1.1	30
151	Prognostic robustness of serum creatinine based AKI definitions in patients with sepsis: a prospective cohort study. BMC Nephrology, 2015, 16, 112.	0.8	16
152	New Methods and Technologies for Measuring Uremic Toxins and Quantifying Dialysis Adequacy. Seminars in Dialysis, 2015, 28, 114-124.	0.7	29
153	European Renal Best Practice Guideline on kidney donor and recipient evaluation and perioperative care: FIGUREÂ1.. Nephrology Dialysis Transplantation, 2015, 30, 1790-1797.	0.4	229
154	Impact of the Uremic Milieu on the Osteogenic Potential of Mesenchymal Stem Cells. PLoS ONE, 2015, 10, e0116468.	1.1	31
155	Transcriptome Analysis in Patients with Chronic Kidney Disease on Hemodialysis Disclosing a Key Role for CD16+CX3CR1+ Monocytes. PLoS ONE, 2015, 10, e0121750.	1.1	13
156	Soluble Tumor Necrosis Factor Receptor 1 and 2 Predict Outcomes in Advanced Chronic Kidney Disease: A Prospective Cohort Study. PLoS ONE, 2015, 10, e0122073.	1.1	59
157	AST-120 for the management of progression of chronic kidney disease. International Journal of Nephrology and Renovascular Disease, 2014, 7, 49.	0.8	53
158	Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population?. Nephrology Dialysis Transplantation, 2014, 29, 2167-2177.	0.4	89
159	Use of vascular access for haemodialysis in Europe: a report from the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2014, 29, 1956-1964.	0.4	79
160	Internal filtration, filtration fraction, and blood flow resistance in high- and low-flux dialyzers. Clinical Hemorheology and Microcirculation, 2014, 58, 455-469.	0.9	7
161	Health economics and European Renal Best Practiceâ€”is it time to bring health economics into evidence-based guideline production in Europe?. Nephrology Dialysis Transplantation, 2014, 29, 1994-1997.	0.4	10
162	Bedside monitoring of anticoagulation in chronic haemodialysis patients treated with tinzaparin. Nephrology Dialysis Transplantation, 2014, 29, 1092-1096.	0.4	8

#	ARTICLE	IF	CITATIONS
163	A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Non-dialysis-dependent Chronic Kidney Disease: an endorsement with some caveats for real-life application. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 490-496.	0.4	76
164	p-Cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 56-64.	0.4	77
165	Clinical Practice Guidelines on diagnosis and treatment of hyponatraemia: response to letter from Otsuka Ltd.. <i>European Journal of Endocrinology</i> , 2014, 171, L5-L6.	1.9	6
166	Clinical Evidence on Hemodiafiltration: A Systematic Review and a Meta-analysis. <i>Seminars in Dialysis</i> , 2014, 27, 119-127.	0.7	117
167	Associations of Self-Reported Physical Activity Types and Levels with Quality of Life, Depression Symptoms, and Mortality in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1702-1712.	2.2	117
168	Uremic toxicity and sclerostin in chronic kidney disease patients. <i>Nephrologie Et Therapeutique</i> , 2014, 10, 463-470.	0.2	71
169	Should screening of renal markers be recommended in a working population?. <i>International Urology and Nephrology</i> , 2014, 46, 1601-1608.	0.6	2
170	Proton-pump inhibitors do not influence serum magnesium levels in renal transplant recipients. <i>Journal of Nephrology</i> , 2014, 27, 707-711.	0.9	15
171	Introduction: Uremic Toxicity – State of the Art 2014. <i>Seminars in Nephrology</i> , 2014, 34, 85-86.	0.6	8
172	The effect of magnesium supplements on early post-transplantation glucose metabolism: a randomized controlled trial. <i>Transplant International</i> , 2014, 27, 895-902.	0.8	38
173	Is Starting Hemodialysis on a Twice-Weekly Regimen a Valid Option?. <i>American Journal of Kidney Diseases</i> , 2014, 64, 165-167.	2.1	19
174	The Uremic Toxicity of Indoxyl Sulfate and p-Cresyl Sulfate. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1897-1907.	3.0	525
175	The Reply. <i>American Journal of Medicine</i> , 2014, 127, e15.	0.6	7
176	Clinical Studies and Chronic Kidney Disease: What Did we Learn Recently?. <i>Seminars in Nephrology</i> , 2014, 34, 164-179.	0.6	20
177	Clinical practice guideline on diagnosis and treatment of hyponatraemia. <i>European Journal of Endocrinology</i> , 2014, 170, G1-G47.	1.9	596
178	Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. <i>Lancet, The</i> , 2014, 383, 1831-1843.	6.3	341
179	Disaster nephrology: crush injury and beyond. <i>Kidney International</i> , 2014, 85, 1049-1057.	2.6	45
180	Renal replacement therapy: how can we contain the costs?. <i>Lancet, The</i> , 2014, 383, 1783-1785.	6.3	16

#	ARTICLE	IF	CITATIONS
181	Severe lactic acidosis in critically ill patients with acute kidney injury treated with renal replacement therapy. <i>Journal of Critical Care</i> , 2014, 29, 650-655.	1.0	21
182	Clinical Practice Guideline on Diagnosis and Treatment of Hyponatraemia. <i>BANTAO Journal</i> , 2014, 12, 65-74.	0.1	2
183	A novel UPLC-MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 1937-1947.	1.9	47
184	Hypomagnesemia and the Risk of Death and GFR Decline in Chronic Kidney Disease. <i>American Journal of Medicine</i> , 2013, 126, 825-831.	0.6	103
185	Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. <i>Kidney International</i> , 2013, 84, 733-744.	2.6	205
186	Association of Dialysate Bicarbonate Concentration With Mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>American Journal of Kidney Diseases</i> , 2013, 62, 738-746.	2.1	133
187	Mixed matrix hollow fiber membranes for removal of protein-bound toxins from human plasma. <i>Biomaterials</i> , 2013, 34, 7819-7828.	5.7	124
188	A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: part 2: renal replacement therapy. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2940-2945.	0.4	70
189	Soluble transferrin receptor in urine, a new biomarker for IgA nephropathy and Henoch-Schönlein purpura nephritis. <i>Clinical Biochemistry</i> , 2013, 46, 591-597.	0.8	30
190	Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1346-1359.	0.4	628
191	Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature*. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 254-273.	0.4	324
192	Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy. <i>International Journal of Cardiology</i> , 2013, 167, 2555-2560.	0.8	38
193	Uremia-Related Oxidative Stress in Leukocytes Is Not Triggered by $\beta_2$ -Microglobulin. , 2013, 23, 456-463.		9
194	Biology of Human Pentraxin 3 (PTX3) in Acute and Chronic Kidney Disease. <i>Journal of Clinical Immunology</i> , 2013, 33, 881-890.	2.0	40
195	Acute kidney injury: an increasing global concern. <i>Lancet</i> , The, 2013, 382, 170-179.	6.3	752
196	Online haemodiafiltration: definition, dose quantification and safety revisited. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 542-550.	0.4	210
197	Protein-Bound Uremic Toxins Stimulate Crosstalk between Leukocytes and Vessel Wall. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1981-1994.	3.0	96
198	An update on uremic toxins. <i>International Urology and Nephrology</i> , 2013, 45, 139-150.	0.6	134

#	ARTICLE	IF	CITATIONS
199	The Relationship of NT-proBNP and Dialysis Parameters with Outcome of Incident Haemodialysis Patients: Results from the Membrane Permeability Outcome Study. <i>Blood Purification</i> , 2013, 35, 216-223.	0.9	6
200	Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 505-517.	0.4	79
201	Less water for haemodialysis: is multiple pass the future pace to go?. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1067-1070.	0.4	2
202	Chronic nicotine exposure and acute kidney injury: new concepts and experimental evidence. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1329-1331.	0.4	8
203	Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients. <i>Kidney International</i> , 2013, 84, 1237-1245.	2.6	67
204	Association between Free Light Chain Levels, and Disease Progression and Mortality in Chronic Kidney Disease. <i>Toxins</i> , 2013, 5, 2058-2073.	1.5	43
205	p-Cresyl Sulfate Promotes Insulin Resistance Associated with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 88-99.	3.0	216
206	Internal Filtration in a High-Flux Dialyzer Quantified by Mean Transit Time of an Albumin-Bound Indicator. <i>ASAIO Journal</i> , 2013, 59, 505-511.	0.9	12
207	Management of Crush Victims in Mass Disasters. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 328-335.	2.2	143
208	Fondaparinux as an alternative to vitamin K antagonists in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 3090-3095.	0.4	9
209	Predicting prognosis in patients with rhabdomyolysis. <i>Nature Reviews Nephrology</i> , 2013, 9, 637-638.	4.1	1
210	The clinical impact of plasma leptin levels in a cohort of chronic kidney disease patients. <i>CKJ: Clinical Kidney Journal</i> , 2013, 6, 63-70.	1.4	16
211	Urinary output and fractional excretion of sodium and urea as indicators of transient versus intrinsic acute kidney injury during early sepsis. <i>Critical Care</i> , 2013, 17, R234.	2.5	78
212	What guidelines should or should not be: implications for guideline production. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1980-1984.	0.4	11
213	Evaluation of Alternatives for Dysfunctional Double Lumen Central Venous Catheters Using a Two-Compartmental Mathematical Model for Different Solutes. <i>International Journal of Artificial Organs</i> , 2013, 36, 17-27.	0.7	5
214	Does the Adequacy Parameter Kt/Vurea Reflect Uremic Toxin Concentrations in Hemodialysis Patients?. <i>PLoS ONE</i> , 2013, 8, e76838.	1.1	64
215	Does P-Cresylglucuronide Have the Same Impact on Mortality as Other Protein-Bound Uremic Toxins?. <i>PLoS ONE</i> , 2013, 8, e67168.	1.1	60
216	Microalbuminuria is more consistent in the presence of cardiovascular risk factors. <i>Journal of Nephrology</i> , 2013, 26, 580-585.	0.9	4

#	ARTICLE	IF	CITATIONS
217	Geographical variability of patient characteristics and treatment patterns affect outcomes for incident hemodialysis patients. <i>Journal of Nephrology</i> , 2013, 26, 119-128.	0.9	1
218	Reimbursement of Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1291-1298.	3.0	121
219	Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 548-556.	0.4	24
220	Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: clinical data and pathophysiological implications. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2388-2396.	0.4	97
221	What can the dialysis physician learn from kinetic modelling beyond Kt/Vurea?. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 4021-4029.	0.4	28
222	Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. <i>Kidney International</i> , 2012, 82, 1297-1303.	2.6	134
223	Home haemodialysis and uraemic toxin removal: does a happy marriage exist?. <i>Nature Reviews Nephrology</i> , 2012, 8, 579-588.	4.1	10
224	Slow Extended Nocturnal Home Hemodialysis Shows Superior Adequacy Compared to In-Center Dialysis: A Mathematical Analysis. <i>Blood Purification</i> , 2012, 34, 219-224.	0.9	4
225	Removal of water-soluble and protein-bound solutes with reversed mid-dilution versus post-dilution haemodiafiltration. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3278-3283.	0.4	22
226	Dialysis water and fluid purity: more than endotoxin. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 4010-4021.	0.4	45
227	Less water for haemodialysis: is multiple pass the future pace to go?. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3975-3978.	0.4	4
228	The ultimate salt war? Uraemic toxins are all that count in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 62-66.	0.4	2
229	Recommendations for the Management of Crush Victims in Mass Disasters. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, i1-i67.	0.4	93
230	Thrombotic microangiopathy: A role for magnesium?. <i>Thrombosis and Haemostasis</i> , 2012, 107, 399-408.	1.8	6
231	Severity of sepsis-induced acute kidney injury in a novel mouse model is age dependent*. <i>Critical Care Medicine</i> , 2012, 40, 2638-2646.	0.4	28
232	A Sad but Forgotten Truth: The Story of Slow-Moving Solutes in Fast Hemodialysis. <i>Seminars in Dialysis</i> , 2012, 25, 505-509.	0.7	37
233	A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 4263-4272.	0.4	460
234	Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP)*. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3736-3745.	0.4	124

#	ARTICLE	IF	CITATIONS
235	Normal and Pathologic Concentrations of Uremic Toxins. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1258-1270.	3.0	758
236	New-Onset Diabetes After Renal Transplantation. <i>Diabetes Care</i> , 2012, 35, 181-188.	4.3	105
237	Tumor Necrosis Factor Receptors: Biology and Therapeutic Potential in Kidney Diseases. <i>American Journal of Nephrology</i> , 2012, 36, 261-270.	1.4	93
238	Hemoglobin A1c Levels and Mortality in the Diabetic Hemodialysis Population. <i>Diabetes Care</i> , 2012, 35, 2527-2532.	4.3	89
239	Mesothelin Levels in Urine are Affected by Glomerular Leakage and Tubular Reabsorption. <i>Clinical Lung Cancer</i> , 2012, 13, 470-474.	1.1	4
240	Protecting the peritoneal membrane: factors beyond peritoneal dialysis solutions. <i>Nature Reviews Nephrology</i> , 2012, 8, 542-550.	4.1	45
241	An Update on Protein-Bound Uremic Retention Solutes. , 2012, 22, 90-94.		41
242	Estimated Glomerular Filtration Rate Is a Poor Predictor of the Concentration of Middle Molecular Weight Uremic Solutes in Chronic Kidney Disease. <i>PLoS ONE</i> , 2012, 7, e44201.	1.1	29
243	Prognostic Implications of Plasma Myoglobin Levels in Patients with Chronic Kidney Disease. <i>International Journal of Artificial Organs</i> , 2012, 35, 959-968.	0.7	1
244	Hypomagnesaemia, the kidney and the vessels. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 4003-4010.	0.4	42
245	An Obituary for GFR as the Main Marker for Kidney Function?. <i>Seminars in Dialysis</i> , 2012, 25, 9-14.	0.7	16
246	Implementation of proteomic biomarkers: making it work. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1027-1036.	1.7	151
247	Statin Use and the Presence of Microalbuminuria. Results from the ERICABEL Trial: A Non-Interventional Epidemiological Cohort Study. <i>PLoS ONE</i> , 2012, 7, e31639.	1.1	11
248	Prognostic implications of plasma myoglobin levels in patients with chronic kidney disease. <i>International Journal of Artificial Organs</i> , 2012, 35, 959-968.	0.7	5
249	Prevalence of chronic kidney disease and its risk factors among family practice patients in Lithuania. <i>Clinical Nephrology</i> , 2012, 78, 198-206.	0.4	0
250	New Uremic Toxins – Which Solutes Should Be Removed?. <i>Contributions To Nephrology</i> , 2011, 168, 117-128.	1.1	35
251	Prognostic Value of Aortic Stiffness and Calcification for Cardiovascular Events and Mortality in Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 153-159.	2.2	191
252	Symmetric Dimethylarginine as a Proinflammatory Agent in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2374-2383.	2.2	119

#	ARTICLE	IF	CITATIONS
253	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines on kidney transplantation: a European Renal Best Practice (ERBP) position statement. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2099-2106.	0.4	77
254	Human Cytomegalovirus and Kidney Transplantation: A Clinician's Update. <i>American Journal of Kidney Diseases</i> , 2011, 58, 118-126.	2.1	118
255	How to use biomarkers efficiently in acute kidney injury. <i>Kidney International</i> , 2011, 79, 1047-1050.	2.6	55
256	Toll-like receptor expression in monocytes in patients with chronic kidney disease and haemodialysis: relation with inflammation. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 955-963.	0.4	57
257	Comparison of removal capacity of two consecutive generations of high-flux dialysers during different treatment modalities. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2624-2630.	0.4	91
258	The relation between hypomagnesaemia and vascular stiffness in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2362-2369.	0.4	44
259	When to start dialysis: updated guidance following publication of the Initiating Dialysis Early and Late (IDEAL) study. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2082-2086.	0.4	140
260	Estimated Glomerular Filtration Rate Is a Poor Predictor of Concentration for a Broad Range of Uremic Toxins. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1266-1273.	2.2	79
261	Aortic Stiffness and Central Wave Reflections Predict Outcome in Renal Transplant Recipients. <i>Hypertension</i> , 2011, 58, 833-838.	1.3	96
262	The Patient as a Limit to Dialysis Technology. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2105-2107.	2.2	4
263	Application of the RIFLE criteria in patients with crush-related acute kidney injury after mass disasters. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 515-524.	0.4	15
264	Defining acute kidney injury: playing hide-and-seek with the unknown man?. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 399-401.	0.4	5
265	Is combined calcium/magnesium phosphate binder really noninferior to sevelamer hydrochloride?. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1442-1443.	0.4	4
266	Serum urea concentration is probably not related to outcome in ICU patients with AKI and renal replacement therapy. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3211-3218.	0.4	19
267	Warning: the unfortunate end of p-cresol as a uraemic toxin. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1464-1467.	0.4	86
268	The role of collagen metabolism in CKD-associated arterial senescence: underestimated and underappreciated. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2726-2728.	0.4	5
269	Influence of switching connection ports of double-lumen permanent tunnelled catheters on total solute removal during dialysis. <i>Journal of Nephrology</i> , 2011, 24, 338-344.	0.9	2
270	Hemodialysis as a Treatment of Severe Accidental Hypothermia. <i>Artificial Organs</i> , 2010, 34, 237-239.	1.0	11

#	ARTICLE	IF	CITATIONS
271	Dialysate and Blood Temperature During Hemodialysis: Comparing Isothermic Dialysis With a Single-Pass Batch System. <i>Artificial Organs</i> , 2010, 34, 1132-1137.	1.0	6
272	Prospective Evaluation of the Change of Predialysis Protein-Bound Uremic Solute Concentration With Postdilution Online Hemodiafiltration. <i>Artificial Organs</i> , 2010, 34, 580-585.	1.0	66
273	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3823-3831.	0.4	85
274	Encapsulating Peritoneal Sclerosis in a Patient with Primary Hyperoxaluria Type 1: A Case Report. <i>Peritoneal Dialysis International</i> , 2010, 30, 108-111.	1.1	0
275	Comparison of Different Methods to Assess Fistula Flow. <i>Blood Purification</i> , 2010, 30, 89-95.	0.9	10
276	Evaluation of peritoneal membrane characteristics: clinical advice for prescription management by the ERBP working group. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2052-2062.	0.4	85
277	Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) Study. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2846-2850.	0.4	137
278	Diagnosis, prevention and treatment of haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP). <i>CKJ: Clinical Kidney Journal</i> , 2010, 3, 234-246.	1.4	53
279	Guanidino Compounds as Cause of Cardiovascular Damage in Chronic Kidney Disease: An in vitro Evaluation. <i>Blood Purification</i> , 2010, 30, 277-287.	0.9	49
280	Catheter-related blood stream infections (CRBSI): a European view. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1753-1756.	0.4	68
281	Body Composition, Hydration, and Related Parameters in Hemodialysis versus Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2010, 30, 208-214.	1.1	91
282	Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2672-2679.	0.4	77
283	Dinucleoside polyphosphates: newly detected uraemic compounds with an impact on leucocyte oxidative burst. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2636-2644.	0.4	10
284	How to remove accumulated iodine in burn-injured patients. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1614-1620.	0.4	10
285	Salt intake induces epithelial-to-mesenchymal transition of the peritoneal membrane in rats. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1688-1696.	0.4	27
286	When to start chronic dialysis: tunnel vision induced by numbers?. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2405-2407.	0.4	7
287	The Gut: The Forgotten Organ in Uremia?. <i>Blood Purification</i> , 2010, 29, 130-136.	0.9	139
288	Educating end-stage renal disease patients on dialysis modality selection. <i>CKJ: Clinical Kidney Journal</i> , 2010, 3, 225-233.	1.4	24

#	ARTICLE	IF	CITATIONS
289	Fanconi syndrome in lymphoma patients: report of the first case series. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2516-2520.	0.4	11
290	De novo Thrombotic Microangiopathy Induced by Cytomegalovirus Infection Leading to Renal Allograft Loss. <i>American Journal of Nephrology</i> , 2010, 32, 491-496.	1.4	23
291	The role of polymer surface degradation and barium sulphate release in the pathogenesis of catheter-related infection. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1207-1213.	0.4	15
292	Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1183-1191.	0.4	371
293	Electrolyte Disturbances and Acute Kidney Injury in Patients With Cancer. <i>Seminars in Nephrology</i> , 2010, 30, 534-547.	0.6	50
294	Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. <i>Kidney International</i> , 2010, 77, 550-556.	2.6	242
295	Uremic Toxins. , 2010, , 219-234.		0
296	Pro/con debate: Continuous versus intermittent dialysis for acute kidney injury: a never-ending story yet approaching the finish?. <i>Critical Care</i> , 2010, 15, 204.	2.5	45
297	Role of aortic calcification, stiffness and wave reflections in cardiovascular risk in dialysis patients: Baseline data from the CORD study. <i>Artery Research</i> , 2010, 4, 81.	0.3	9
298	Uraemic toxins for consideration by the cardiologistâ€”Beyond traditional and non-traditional cardiovascular risk factors. <i>Atherosclerosis</i> , 2010, 211, 381-383.	0.4	18
299	Renal Disaster Relief Task Force in Haiti earthquake. <i>Lancet, The</i> , 2010, 375, 1162-1163.	6.3	50
300	Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 2424-2437.	2.5	434
301	Recommendations for Biomarker Identification and Qualification in Clinical Proteomics. <i>Science Translational Medicine</i> , 2010, 2, 46ps42.	5.8	273
302	Towards a Rational Screening Strategy for Albuminuria: Results from the Unreferred Renal Insufficiency Trial. <i>PLoS ONE</i> , 2010, 5, e13328.	1.1	7
303	Glomerular Filtration Rate Is a Confounder for the Measurement of Soluble Mesothelin in Serum. <i>Clinical Chemistry</i> , 2009, 55, 1431-1433.	1.5	33
304	Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1429-1435.	0.4	124
305	Renal disaster relief: from theory to practice. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1730-1735.	0.4	46
306	Why do patients on peritoneal dialysis have low blood levels of protein-bound solutes?. <i>Nature Reviews Nephrology</i> , 2009, 5, 130-131.	4.1	32

#	ARTICLE	IF	CITATIONS
307	Hurricane Katrina and chronic dialysis patients: better tidings than originally feared?. <i>Kidney International</i> , 2009, 76, 687-689.	2.6	17
308	Impact of increasing haemodialysis frequency versus haemodialysis duration on removal of urea and guanidino compounds: a kinetic analysis. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2225-2232.	0.4	40
309	Treatment of type 2 diabetes in chronic kidney disease: meekly follow the herd or call to arms?. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2286-2287.	0.4	1
310	We don't need no education ... . (Pink Floyd, The Wall ) Multidisciplinary predialysis education programmes: pass or fail?. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3277-3279.	0.4	13
311	Renal disaster relief in Europe: the experience at L'Aquila, Italy, in April 2009. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3251-3255.	0.4	19
312	The future of European Nephrology 'Guidelines'--a declaration of intent by European Renal Best Practice (ERBP). <i>CKJ: Clinical Kidney Journal</i> , 2009, 2, 213-221.	1.4	7
313	Did 20 Years of Technological Innovations in Hemodialysis Contribute to Better Patient Outcomes?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, S30-S40.	2.2	50
314	Effect of Membrane Permeability on Survival of Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 645-654.	3.0	364
315	Flow cytometric calcium flux assay: Evaluation of cytoplasmic calcium kinetics in whole blood leukocytes. <i>Journal of Immunological Methods</i> , 2009, 348, 74-82.	0.6	19
316	Correspondence: Dialysate Calcium and the European Best Practice Guidelines on Hemodynamic Instability. <i>Seminars in Dialysis</i> , 2009, 22, 311-311.	0.7	0
317	PROGRESS IN UREMIC TOXIN RESEARCH: Progress in Uremic Toxin Research: An Introduction. <i>Seminars in Dialysis</i> , 2009, 22, 321-322.	0.7	7
318	PROGRESS IN UREMIC TOXIN RESEARCH: The Role of EUTox in Uremic Toxin Research. <i>Seminars in Dialysis</i> , 2009, 22, 323-328.	0.7	27
319	PROGRESS IN UREMIC TOXIN RESEARCH: Protein-Bound Toxins Update 2009. <i>Seminars in Dialysis</i> , 2009, 22, 334-339.	0.7	139
320	PROGRESS IN UREMIC TOXIN RESEARCH: Guanidino Compounds as Uremic (Neuro)Toxins. <i>Seminars in Dialysis</i> , 2009, 22, 340-345.	0.7	103
321	PROGRESS IN UREMIC TOXIN RESEARCH: Phosphate Metabolism in Chronic Kidney Disease: From Pathophysiology to Clinical Management. <i>Seminars in Dialysis</i> , 2009, 22, 357-362.	0.7	15
322	Progress in Uremic Toxin Research: Genetics/Genomics in Chronic Kidney Disease Towards Personalized Medicine?. <i>Seminars in Dialysis</i> , 2009, 22, 417-422.	0.7	25
323	PROGRESS IN UREMIC TOXIN RESEARCH: Platelet/Leukocyte Activation, Inflammation, and Uremia. <i>Seminars in Dialysis</i> , 2009, 22, 423-427.	0.7	42
324	PROGRESS IN UREMIC TOXIN RESEARCH: Conservative Treatment of the Uremic Syndrome. <i>Seminars in Dialysis</i> , 2009, 22, 449-453.	0.7	1

#	ARTICLE	IF	CITATIONS
325	Evaluation of Urine Proteome Pattern Analysis for Its Potential To Reflect Coronary Artery Atherosclerosis in Symptomatic Patients. <i>Journal of Proteome Research</i> , 2009, 8, 335-345.	1.8	98
326	Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1551-1558.	2.2	740
327	Epidemiology of infection in critically ill patients with acute renal failure. <i>Critical Care Medicine</i> , 2009, 37, 2203-2209.	0.4	60
328	Evolution of protein-bound uraemic solutes during predilution haemofiltration. <i>Journal of Nephrology</i> , 2009, 22, 352-7.	0.9	22
329	What is new in uremic toxicity?. <i>Pediatric Nephrology</i> , 2008, 23, 1211-1221.	0.9	182
330	CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. <i>Proteomics - Clinical Applications</i> , 2008, 2, 964-973.	0.8	178
331	Opinion: What Are the Potential Solutions for the Problems with Current Methods for Quantifying Hemodialysis?. <i>Seminars in Dialysis</i> , 2008, 21, 407-409.	0.7	3
332	Urea Kinetic Modeling: Comparing the Options. <i>Artificial Organs</i> , 2008, 17, 813-816.	1.0	2
333	Acute kidney injury. <i>Lancet, The</i> , 2008, 372, 1863-1865.	6.3	111
334	Vitamin D Binding Protein and the Need for Vitamin D in Hemodialysis Patients. , 2008, 18, 400-407.		10
335	Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 348-354.	0.4	178
336	European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP). <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2162-2166.	0.4	59
337	Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 562-570.	0.4	156
338	Uraemic toxins and cardiovascular disease: in vitro research versus clinical outcome studies. <i>CKJ: Clinical Kidney Journal</i> , 2008, 1, 2-10.	1.4	11
339	All high-flux membranes are equal but some high-flux membranes are less equal than others. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 1481-1483.	0.4	5
340	Why less success of the peritoneal dialysis programmes in Europe?. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 1478-1481.	0.4	31
341	An infallible recipe? A story of cinnamon, soufflé and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2729-2732.	0.4	3
342	Impact of local circumstances on outcome of renal casualties in major disasters. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 907-912.	0.4	25

#	ARTICLE	IF	CITATIONS
343	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 719-727.	0.4	41
344	The MPO Study: Just a European HEMO Study or Something Very Different?. <i>Blood Purification</i> , 2008, 26, 100-104.	0.9	33
345	Exploring the Uremic Toxins Using Proteomic Technologies. , 2008, 160, 159-171.		19
346	Evidence for Internal Filtration in the Genius® System, Performing Slow Low Efficient Daily Dialysis in the Intensive Care Unit. <i>Blood Purification</i> , 2008, 26, 460-467.	0.9	9
347	Uremic Toxins: Do We Know Enough to Explain Uremia?. <i>Blood Purification</i> , 2008, 26, 77-81.	0.9	32
348	The prevention of acute kidney injury: an in-depth narrative review Part 1: volume resuscitation and avoidance of drug- and nephrotoxin-induced AKI. <i>CKJ: Clinical Kidney Journal</i> , 2008, 1, 392-402.	1.4	8
349	Contrast-enhanced ultrasonography with microbubbles for successful screening of kidney tumours. <i>CKJ: Clinical Kidney Journal</i> , 2008, 1, 469-470.	1.4	0
350	A Bench to Bedside View of Uremic Toxins. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 863-870.	3.0	287
351	Marconi Revisited. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1253-1255.	3.0	17
352	Do we need new indicators of dialysis adequacy based on middle-molecule removal?. <i>Nature Clinical Practice Nephrology</i> , 2008, 4, 174-175.	2.0	24
353	The role of the Renal Disaster Relief Task Force. <i>Nature Clinical Practice Nephrology</i> , 2008, 4, 347-347.	2.0	8
354	Two-tier approach for the detection of alpha-galactosidase A deficiency in kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 4044-4048.	0.4	17
355	Acute central haemodynamic effects induced by intraperitoneal glucose instillation. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 4029-4035.	0.4	12
356	A novel bio-assay increases the detection yield of microbiological impurity of dialysis fluid, in comparison to the LAL-test. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 548-554.	0.4	29
357	A tantalizing question: Ferrari or Rolls Royce? A meta-analysis on the ideal renal replacement modality for acute kidney injury at the intensive care unit*. <i>Critical Care Medicine</i> , 2008, 36, 649-650.	0.4	8
358	Acute renal problems in the critically ill cancer patient. <i>Current Opinion in Critical Care</i> , 2008, 14, 635-646.	1.6	40
359	Therapeutic Interventions Favorably Influencing Delayed and Slow Graft Function in Kidney Transplantation: Mission Impossible?. <i>Transplantation</i> , 2008, 85, S31-S37.	0.5	37
360	Acute Central Hemodynamic Effects of a Volume Exchange in Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2008, 28, 142-148.	1.1	17

#	ARTICLE	IF	CITATIONS
361	Acute central hemodynamic effects of a volume exchange in peritoneal dialysis. <i>Peritoneal Dialysis International</i> , 2008, 28, 142-8.	1.1	10
362	The middle-molecule hypothesis 30 years after: lost and rediscovered in the universe of uremic toxicity?. <i>Journal of Nephrology</i> , 2008, 21, 146-60.	0.9	53
363	Residual renal function and volume status in peritoneal dialysis patients: a conflict of interest?. <i>Journal of Nephrology</i> , 2008, 21, 299-304.	0.9	18
364	Early detection of patients at high risk for acute kidney injury during disasters: development of a scoring system based on the Bam earthquake experience. <i>Journal of Nephrology</i> , 2008, 21, 776-82.	0.9	20
365	The relation between salt, volume, and hypertension: clinical evidence for forgotten but still valid basic physiology. <i>Peritoneal Dialysis International</i> , 2008, 28, 596-600.	1.1	8
366	Mass-Spectrometric Identification of a Novel Angiotensin Peptide in Human Plasma. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 297-302.	1.1	165
367	Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2006-2012.	0.4	93
368	EBPG guideline on haemodynamic instability. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, ii22-ii44.	0.4	191
369	Review on uraemic solutes II Variability in reported concentrations: causes and consequences. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3115-3121.	0.4	49
370	Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro towards a standardized approach for research on uraemia. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3381-3390.	0.4	74
371	End-stage disease of native kidneys in a patient with biopsy-proven Arndt-Gottron scleromyxoedema and recurrence in the transplanted kidney. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3065-3069.	0.4	3
372	Temperature and concentration distribution within the Genius(R) dialysate container. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2962-2969.	0.4	10
373	Goodpasture's syndrome associated with autoimmune thrombotic thrombocytopenic purpura an unusual case. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3672-3673.	0.4	15
374	Two-tier approach for the detection of alpha-galactosidase A deficiency in a predominantly female haemodialysis population. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 294-300.	0.4	31
375	Guanidino compounds after creatine supplementation in renal failure patients and their relation to inflammatory status. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 1330-1335.	0.4	26
376	Arterial stiffness and wave reflections in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3021-3027.	0.4	40
377	EBPG guideline on dialysis strategies. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, ii5-ii21.	0.4	175
378	Relation between acute kidney injury and multiple-organ failure: The chicken and the egg question*. <i>Critical Care Medicine</i> , 2007, 35, 316-317.	0.4	16

#	ARTICLE	IF	CITATIONS
379	Approach for guideline development. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, ii1-ii4.	0.4	2
380	Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. <i>Clinica Chimica Acta</i> , 2007, 379, 87-94.	0.5	47
381	Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium. <i>Bone</i> , 2007, 41, 698-703.	1.4	48
382	The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. <i>European Heart Journal</i> , 2007, 28, 478-483.	1.0	157
383	EBPG Guideline on Nutrition. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, ii45-ii87.	0.4	442
384	EBPG on Vascular Access. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, ii88-ii117.	0.4	475
385	Health Implications of Antimicrobial Resistance for Patients With Acute Kidney Injury and Bloodstream Infection. <i>Infection Control and Hospital Epidemiology</i> , 2007, 28, 1107-1110.	1.0	16
386	Complex Compartmental Behavior of Small Water-Soluble Uremic Retention Solutes: Evaluation by Direct Measurements in Plasma and Erythrocytes. <i>American Journal of Kidney Diseases</i> , 2007, 50, 279-288.	2.1	80
387	Inconsistency of Reported Uremic Toxin Concentrations. <i>Artificial Organs</i> , 2007, 31, 600-611.	1.0	53
388	Belgium's mixed private/public health care system and its impact on the cost of end-stage renal disease. <i>International Journal of Health Care Finance and Economics</i> , 2007, 7, 133-148.	1.2	29
389	The fate of older diabetic patients on peritoneal dialysis: myths and mysteries and suggestions for further research. <i>Peritoneal Dialysis International</i> , 2007, 27, 611-8.	1.1	8
390	Disaster management of chronic dialysis patients. <i>American Journal of Disaster Medicine</i> , 2007, 2, 96-106.	0.1	7
391	The changing epidemiology of acute renal failure. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 364-377.	2.0	229
392	Management of Crush-Related Injuries after Disasters. <i>New England Journal of Medicine</i> , 2006, 354, 1052-1063.	13.9	281
393	Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2834-2840.	0.4	18
394	THE EPIDEMIC OF CARDIO-VASCULAR DISEASE IN RENAL FAILURE: WHERE DOES IT COME FROM, WHERE DO WE GO?. <i>Acta Clinica Belgica</i> , 2006, 61, 205-211.	0.5	5
395	ASSESSMENT OF PRESSURE PROFILES IN THE GENIUS?? SYSTEM TO ENHANCE INTERNAL FILTRATION. <i>ASAIO Journal</i> , 2006, 52, 70A.	0.9	0
396	Online Hemodiafiltration. <i>Artificial Organs</i> , 2006, 30, 579-585.	1.0	18

#	ARTICLE	IF	CITATIONS
397	Epidemiologic Aspects of the Bam Earthquake in Iran: The Nephrologic Perspective. American Journal of Kidney Diseases, 2006, 47, 428-438.	2.1	83
398	The importance of standardization of creatinine in the implementation of guidelines and recommendations for CKD: implications for CKD management programmes. Nephrology Dialysis Transplantation, 2006, 21, 77-83.	0.4	93
399	Intervention of the renal disaster relief task force (RDRTF) in the Kashmir earthquake. Nephrology Dialysis Transplantation, 2006, 21, 40-40.	0.4	8
400	Clamping of the dialysate outlet line in the GeniusÂ® dialysis system does not alter dialysate flow or clearances. Nephrology Dialysis Transplantation, 2006, 21, 1069-1072.	0.4	6
401	Chronic kidney disease in adultsâ€™UK guidelines for identification, management and referral. Nephrology Dialysis Transplantation, 2006, 21, 1776-1777.	0.4	61
402	Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro peritoneal dialysis. Nephrology Dialysis Transplantation, 2006, 22, 53-58.	0.4	31
403	Peritoneal Dialysis in Europe: An Analysis of Its Rise and Fall. Blood Purification, 2006, 24, 107-114.	0.9	21
404	The Rise of Prevalence and the Fall of Mortality of Patients with Acute Renal Failure: What the Analysis of Two Databases Does and Does Not Tell Us. Journal of the American Society of Nephrology: JASN, 2006, 17, 923-925.	3.0	73
405	What Is Uremia? Retention versus Oxidation. Blood Purification, 2006, 24, 33-38.	0.9	25
406	The Personal Dialysis Capacity Test Is Superior to the Peritoneal Equilibration Test to Discriminate Inflammation as the Cause of Fast Transport Status in Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 269-274.	2.2	47
407	Defining Acute Renal Failure: RIFLE and Beyond: Table 1.. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 1314-1319.	2.2	145
408	P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrology Dialysis Transplantation, 2006, 22, 592-596.	0.4	259
409	Is peritoneal dialysis associated with increased cardiovascular morbidity and mortality?. Peritoneal Dialysis International, 2006, 26, 429-34.	1.1	8
410	Animal models in peritoneal dialysis: a story of kangaroos and ostriches. Peritoneal Dialysis International, 2006, 26, 571-3.	1.1	4
411	Efficacy of Erythropoietin Administration in the Treatment of Anemia Immediately After Renal Transplantation. Transplantation, 2005, 79, 367-368.	0.5	50
412	Survival and Complications of Indwelling Venous Catheters for Permanent Use in Hemodialysis Patients. Artificial Organs, 2005, 29, 399-405.	1.0	70
413	The European Artificial Organ Scene: Present Status. Artificial Organs, 2005, 29, 498-506.	1.0	9
414	Right atrial thrombus in an asymptomatic hemodialysis patient with malfunctioning catheter and patent foramen ovale. Hemodialysis International, 2005, 9, 236-240.	0.4	17

#	ARTICLE	IF	CITATIONS
415	Kinetic behavior of urea is different from that of other water-soluble compounds: The case of the guanidino compounds. <i>Kidney International</i> , 2005, 67, 1566-1575.	2.6	113
416	Dialysate partitioning in the Genius <sup>®</sup> batch hemodialysis system: Effect of temperature and solute concentration. <i>Kidney International</i> , 2005, 67, 2470-2476.	2.6	16
417	Uridine adenosine tetraphosphate: a novel endothelium- derived vasoconstrictive factor. <i>Nature Medicine</i> , 2005, 11, 223-227.	15.2	147
418	Efficiency of the Genius <sup>®</sup> Batch Hemodialysis System With Low Serum Solute Concentrations: The Case of Lithium Intoxication Therapy. <i>American Journal of Kidney Diseases</i> , 2005, 46, e95-e99.	2.1	8
419	Noninvasive Assessment of Local Pulse Pressure. <i>Hypertension</i> , 2005, 46, 244-248.	1.3	163
420	Sevelamer Prevents Uremia-Enhanced Atherosclerosis Progression in Apolipoprotein E <sup>-/-</sup> Deficient Mice. <i>Circulation</i> , 2005, 112, 2875-2882.	1.6	139
421	Chronic kidney disease as cause of cardiovascular morbidity and mortality. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 1048-1056.	0.4	523
422	Detection of Angiotensin II in Supernatants of Stimulated Mononuclear Leukocytes by Matrix-Assisted Laser Desorption Ionization Time-of-Flight/Time-of-Flight Mass Analysis. <i>Hypertension</i> , 2005, 46, 591-597.	1.3	27
423	Assessment of renal function in recently admitted critically ill patients with normal serum creatinine. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 747-753.	0.4	210
424	PREDICTION OF DIALYSIS THERAPY FOR ADEQUATE REMOVAL OF UREMIC TOXINS, OTHER THAN UREA. <i>ASAIO Journal</i> , 2005, 51, 58A.	0.9	0
425	In vivo distribution and fractionation of indium in rats after subcutaneous and oral administration of [ <sup>114m</sup> In]InAs. <i>Journal of Environmental Monitoring</i> , 2005, 7, 365.	2.1	16
426	Disseminated Mycobacterium avium complex infection in a renal transplant patient. <i>European Journal of Internal Medicine</i> , 2005, 16, 53-55.	1.0	8
427	Acute renal failure. <i>Lancet, The</i> , 2005, 365, 417-30.	6.3	415
428	Relationship between fluid status and its management on acute renal failure (ARF) in intensive care unit (ICU) patients with sepsis: a prospective analysis. <i>Journal of Nephrology</i> , 2005, 18, 54-60.	0.9	96
429	Sodium bicarbonate versus THAM in ICU patients with mild metabolic acidosis. <i>Journal of Nephrology</i> , 2005, 18, 303-7.	0.9	56
430	Intermittent Hemodialysis for Acute Renal Failure Patients - An Update. , 2004, 144, 255-263.		0
431	Which dialyser membrane to choose?. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 293-296.	0.4	64
432	Features of Chronic Hemodialysis Practice after the Marmara Earthquake. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1071-1076.	3.0	56

#	ARTICLE	IF	CITATIONS
433	Interleukin/cytokine profiles in haemodialysis and in continuous peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, v41-v45.	0.4	28
434	Proteomics: a novel tool to unravel the patho-physiology of uraemia. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 3068-3077.	0.4	121
435	Effect of Nosocomial Bloodstream Infection on the Outcome of Critically Ill Patients with Acute Renal Failure Treated with Renal Replacement Therapy. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 454-462.	3.0	86
436	The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. <i>Kidney International</i> , 2004, 65, 442-451.	2.6	421
437	In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. <i>Kidney International</i> , 2004, 65, 2184-2192.	2.6	92
438	The burden of kidney disease: Improving global outcomes. <i>Kidney International</i> , 2004, 66, 1310-1314.	2.6	376
439	In vitro evidence for immune activating effect of specific AGE structures retained in uremia. <i>Kidney International</i> , 2004, 66, 1873-1880.	2.6	53
440	Biochemical and Clinical Evidence for Uremic Toxicity. <i>Artificial Organs</i> , 2004, 28, 248-253.	1.0	47
441	Clinical characteristics of patients developing ARF due to sepsis/systemic inflammatory response syndrome: results of a prospective study. <i>American Journal of Kidney Diseases</i> , 2004, 43, 817-824.	2.1	155
442	The impact of metrological traceability on the validity of creatinine measurement as an index of renal function. <i>Accreditation and Quality Assurance</i> , 2004, 10, 15-19.	0.4	2
443	Identification of some arsenic species in human urine and blood after ingestion of Chinese seaweed <i>Laminaria</i> . <i>Journal of Analytical Atomic Spectrometry</i> , 2004, 19, 58.	1.6	52
444	Delayed graft function in renal transplantation. <i>Current Opinion in Critical Care</i> , 2004, 10, 489-498.	1.6	57
445	P-cresol, a uremic retention solute, alters the endothelial barrier function in vitro. <i>Thrombosis and Haemostasis</i> , 2004, 92, 140-150.	1.8	85
446	Effect of gender on various parameters of crush syndrome victims of the Marmara earthquake. <i>Journal of Nephrology</i> , 2004, 17, 399-404.	0.9	8
447	Back to the Future: Middle Molecules, High Flux Membranes, and Optimal Dialysis. <i>Hemodialysis International</i> , 2003, 7, 52-57.	0.4	16
448	Uremic Toxins: Removal with Different Therapies. <i>Hemodialysis International</i> , 2003, 7, 162-167.	0.4	6
449	An Overview of Uremic Toxicity. <i>Hemodialysis International</i> , 2003, 7, 156-161.	0.4	25
450	Comparative kinetics of the uremic toxin p-cresol versus creatinine in rats with and without renal failure. <i>Kidney International</i> , 2003, 64, 1365-1373.	2.6	13

#	ARTICLE	IF	CITATIONS
451	Effects of uremic ultrafiltrate on the regulation of the parathyroid cell cycle by calcitriol. <i>Kidney International</i> , 2003, 63, 732-737.	2.6	14
452	Studies on dialysate mixing in the Genius® single-pass batch system for hemodialysis therapy. <i>Kidney International</i> , 2003, 63, 1540-1547.	2.6	47
453	Involvement of voltage- and ligand-gated Ca <sup>2+</sup> channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins. <i>Kidney International</i> , 2003, 63, 1764-1775.	2.6	56
454	Review on uremic toxins: Classification, concentration, and interindividual variability. <i>Kidney International</i> , 2003, 63, 1934-1943.	2.6	1,379
455	New insights in uremic toxins. <i>Kidney International</i> , 2003, 63, S6-S10.	2.6	174
456	Randomised Long-Term Comparison of Tinzaparin and Dalteparin in Haemodialysis. <i>Clinical Drug Investigation</i> , 2003, 23, 85-97.	1.1	15
457	Reevaluation of Formulas for Predicting Creatinine Clearance in Adults and Children, Using Compensated Creatinine Methods. <i>Clinical Chemistry</i> , 2003, 49, 1011-1014.	1.5	63
458	Acute Renal Failure in Patients with Sepsis in a Surgical ICU: Predictive Factors, Incidence, Comorbidity, and Outcome. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1022-1030.	3.0	388
459	Toxicity of Free p-Cresol: A Prospective and Cross-Sectional Analysis. <i>Clinical Chemistry</i> , 2003, 49, 470-478.	1.5	114
460	Urinary excretion of the uraemic toxin p-cresol in the rat: contribution of glucuronidation to its metabolization. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1299-1306.	0.4	35
461	Outcome in a post-cardiac surgery population with acute renal failure requiring dialysis: does age make a difference?. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 732-736.	0.4	57
462	Specific characteristics of peritoneal leucocyte populations during sterile peritonitis associated with icodextrin CAPD fluids. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1648-1653.	0.4	12
463	Uraemic toxins and cardiovascular disease. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 463-466.	0.4	61
464	CENTRAL VEIN HEMODIALYSIS CATHETERS AND INFECTION: A PLEA FOR TIMELY REFERRAL AND APPROPRIATE HYGIENIC MEASURES. <i>Acta Clinica Belgica</i> , 2003, 58, 342-344.	0.5	4
465	Prevention and nondialytic treatment of acute renal failure. <i>Current Opinion in Critical Care</i> , 2003, 9, 481-490.	1.6	58
466	The organization and interventions of the ISN Renal Disaster Relief Task Force. <i>Advances in Chronic Kidney Disease</i> , 2003, 10, 93-99.	2.2	24
467	Clinical findings in the renal victims of a catastrophic disaster: the Marmara earthquake. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1942-1949.	0.4	96
468	An overview of morbidity and mortality in patients with acute renal failure due to crush syndrome: the Marmara earthquake experience. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 33-40.	0.4	121

#	ARTICLE	IF	CITATIONS
469	Loop Diuretics for Patients With Acute Renal Failure. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 2599.	3.8	51
470	The Marmara earthquake: admission laboratory features of patients with nephrological problems. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1025-1031.	0.4	25
471	Peritoneal-dialysis-related peritonitis: the art of rope-dancing. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1878-1882.	0.4	23
472	Initiation of dialysis--is the problem solved by NECOSAD?. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1550-1552.	0.4	14
473	No early respiratory benefit with CVVHDF in patients with acute renal failure and acute lung injury. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 2153-2158.	0.4	16
474	In vitro evaluation of motilin agonism by macrolide immunosuppressive drugs. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 973-977.	0.4	7
475	The role of trace elements in uraemic toxicity. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 2-8.	0.4	76
476	Treatment Modalities and Outcome of the Renal Victims of the Marmara Earthquake. <i>Nephron</i> , 2002, 92, 64-71.	0.9	46
477	Lessons learned from the Marmara disaster: Time period under the rubble. <i>Critical Care Medicine</i> , 2002, 30, 2443-2449.	0.4	48
478	Peritoneal dialysis catheters: the beauty of simplicity or the glamour of technicality? Percutaneous vs surgical placement. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 210-212.	0.4	19
479	Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. <i>American Journal of Kidney Diseases</i> , 2002, 40, 339-347.	2.1	155
480	Acute renal failure due to crush syndrome during Marmara earthquake. <i>American Journal of Kidney Diseases</i> , 2002, 40, 682-689.	2.1	40
481	Behaviour of vanadate and vanadium-transferrin complex on different anion-exchange columns. Application to in vivo <sup>48</sup> V-labelled rat serum. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 775, 143-152.	1.2	14
482	Renal replacement therapies in the aftermath of the catastrophic Marmara earthquake. <i>Kidney International</i> , 2002, 62, 2264-2271.	2.6	58
483	P-cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. <i>Kidney International</i> , 2002, 62, 1999-2009.	2.6	88
484	Dissociation Between Dialysis Adequacy and Kt/V. <i>Seminars in Dialysis</i> , 2002, 15, 3-7.	0.7	20
485	The Dialytic Management of Acute Renal Failure in the Elderly. <i>Seminars in Dialysis</i> , 2002, 15, 127-132.	0.7	10
486	Peritoneal Dialysis in Anuric Patients: Concerns and Cautions. <i>Seminars in Dialysis</i> , 2002, 15, 305-310.	0.7	15

#	ARTICLE	IF	CITATIONS
487	The Other Side of the Coin: Impact of Toxin Generation and Nutrition on the Uremic Syndrome. <i>Seminars in Dialysis</i> , 2002, 15, 311-314.	0.7	7
488	Automated Peritoneal Dialysis Symposium: The Role of APD in the Improvement of Outcomes in an ESRD Program. <i>Seminars in Dialysis</i> , 2002, 15, 422-426.	0.7	8
489	Fractionation of vanadium in urine of Wistar rats as a function of time after intraperitoneal injection. <i>Journal of Inorganic Biochemistry</i> , 2002, 90, 71-77.	1.5	5
490	Fractionation of vanadium complexes in serum, packed cells and tissues of Wistar rats by means of gel filtration and anion-exchange chromatography. <i>Journal of Biological Inorganic Chemistry</i> , 2002, 7, 884-890.	1.1	49
491	Influence of dialysate on gastric emptying time in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2002, 22, 32-8.	1.1	18
492	The impact of healthy start peritoneal dialysis on the evolution of residual renal function and nutrition parameters. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2002, 18, 44-8.	0.1	5
493	Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. <i>American Journal of Medicine</i> , 2001, 110, 438-441.	0.6	242
494	Kinetics of the protein-bound, lipophilic, uremic toxin p-cresol in healthy rats. <i>Life Sciences</i> , 2001, 69, 2237-2248.	2.0	24
495	Severe hyponatraemia and hypouricaemia in Gitelman's syndrome. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 2250-2252.	0.4	8
496	Reply. <i>Blood Purification</i> , 2001, 19, 71-72.	0.9	0
497	Non-ideal behaviour of free vanadate on a Superose 12 size-exclusion column. Application to in vivo <sup>48</sup> V-labelled rat spleen homogenate. <i>Biomedical Applications</i> , 2001, 757, 21-29.	1.7	5
498	Diabetes-induced microvascular dysfunction in the hydronephrotic kidney: Role of nitric oxide. <i>Kidney International</i> , 2001, 60, 202-210.	2.6	55
499	Intervention of the Renal Disaster Relief Task Force in the 1999 Marmara, Turkey earthquake. <i>Kidney International</i> , 2001, 59, 783-791.	2.6	73
500	The Marmara earthquake: Epidemiological analysis of the victims with nephrological problems. <i>Kidney International</i> , 2001, 60, 1114-1123.	2.6	97
501	Protein-bound uremic solutes: The forgotten toxins. <i>Kidney International</i> , 2001, 59, S266-S270.	2.6	77
502	Uremic toxins and peritoneal dialysis. <i>Kidney International</i> , 2001, 59, S292-S297.	2.6	30
503	Relationship between gastric emptying and clinical and biochemical factors in chronic haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 1850-1855.	0.4	59
504	The anti-proliferative effect of calcitriol on HL-60 cells is neutralized by uraemic biological fluids. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 246-252.	0.4	4

#	ARTICLE	IF	CITATIONS
505	IsKt/VUrea a Satisfactory Measure for Dosing the Newer Dialysis Regimens?. <i>Seminars in Dialysis</i> , 2001, 14, 12-14.	0.7	4
506	Comparison of survival on CAPD and haemodialysis: statistical pitfalls. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 307-311.	0.4	27
507	Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 50-57.	0.4	243
508	Acute renal failure related to the crush syndrome: towards an era of seismo-nephrology?. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 1517-1521.	0.4	75
509	Delayed gastric emptying in dyspeptic chronic hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2000, 36, 962-968.	2.1	95
510	Vitamin E bonded cellulose membrane and hemodialysis bioincompatibility: Absence of an acute benefit on expression of leukocyte surface molecules. <i>American Journal of Kidney Diseases</i> , 2000, 36, 1140-1146.	2.1	18
511	Continuous Ambulatory Peritoneal Dialysis Peritonitis due to <i>Enterococcus cecorum</i> . <i>Journal of Clinical Microbiology</i> , 2000, 38, 3511-3512.	1.8	27
512	An Evaluation of an Integrative Care Approach for End-Stage Renal Disease Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 116-125.	3.0	235
513	Rhabdomyolysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 1553-1561.	3.0	576
514	p-Cresol: a toxin revealing many neglected but relevant aspects of uraemic toxicity. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 2813-2815.	0.4	100
515	Dialysing the patient with acute renal failure in the ICU: the emperor's clothes?. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 2570-2573.	0.4	40
516	Intradialytic Parenteral Nutrition in Malnourished Hemodialysis Patients: A Prospective Long-Term Study. <i>Journal of Parenteral and Enteral Nutrition</i> , 1999, 23, 90-95.	1.3	58
517	Study by means of high-performance liquid chromatography of solutes that decrease theophylline/protein binding in the serum of uremic patients. <i>Journal of Chromatography A</i> , 1999, 847, 141-153.	1.8	27
518	Acute renal failure in the elderly. <i>Geriatric Nephrology and Urology</i> , 1999, 9, 153-165.	0.4	7
519	Reduced incidence of acute renal graft failure in patients treated with peritoneal dialysis compared with hemodialysis. <i>American Journal of Kidney Diseases</i> , 1999, 33, 934-940.	2.1	84
520	Does biocompatibility of dialysis membranes affect recovery of renal function and survival?. <i>Lancet</i> , The, 1999, 354, 1316-1318.	6.3	30
521	In Vitro Methylation of Arsenite by Rabbit Liver Cytosol: Effect of Metal Ions, Metal Chelating Agents, Methyltransferase Inhibitors and Uremic Toxins. <i>Drug and Chemical Toxicology</i> , 1999, 22, 613-628.	1.2	32
522	Intradialytic Parenteral Nutrition in Malnourished Hemodialysis Patients. Review of the Literature. <i>Mineral and Electrolyte Metabolism</i> , 1999, 25, 324-332.	1.1	8

#	ARTICLE	IF	CITATIONS
523	Recombinant Hirudin. <i>BioDrugs</i> , 1999, 11, 417-429.	2.2	9
524	Cytokine Removal during Continuous Hemofiltration in Septic Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 846-853.	3.0	364
525	Pathophysiologic Effects of Uremic Retention Solutes. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 1815-1823.	3.0	201
526	Prevalence of histological $\beta_2$ -microglobulin amyloidosis in CAPD patients compared with hemodialysis patients. <i>Kidney International</i> , 1998, 54, 956-959.	2.6	55
527	A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. <i>Clinica Chimica Acta</i> , 1998, 278, 1-21.	0.5	93
528	Chemical speciation of arsenic in serum of uraemic patients. <i>Analyst</i> , 1998, 123, 13-17.	1.7	27
529	Application of Kohonen neural networks for the non-morphological distinction between glomerular and tubular renal disease. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 59-66.	0.4	13
530	Recent Developments in Osmotic Agents for Peritoneal Dialysis. <i>Advances in Chronic Kidney Disease</i> , 1998, 5, 218-231.	2.2	15
531	Consequences of Using Glucose in Peritoneal Dialysis Fluid. <i>Seminars in Dialysis</i> , 1998, 11, 271-275.	0.7	7
532	Binding of indole-3-acetic acid to human serum albumin and competition with l-tryptophan. <i>Clinica Chimica Acta</i> , 1997, 265, 183-192.	0.5	35
533	HPLC fractions of human uremic plasma inhibit the RBC membrane calcium pump. <i>Kidney International</i> , 1997, 51, 1042-1052.	2.6	20
534	Histological prevalence of $\beta_2$ -microglobulin amyloidosis in hemodialysis: A prospective post-mortem study. <i>Kidney International</i> , 1997, 51, 1928-1932.	2.6	146
535	Estimation of parameters in a two-pool urea kinetic model for hemodialysis. <i>Medical Engineering and Physics</i> , 1997, 19, 69-76.	0.8	20
536	Novel Frameshift Mutation in a Heterozygous Woman with Fabry Disease and End-Stage Renal Failure. <i>American Journal of Nephrology</i> , 1996, 16, 352-357.	1.4	20
537	Relationship Between Biocompatibility and Neutrophil Function in Hemodialysis Patients. <i>Advances in Chronic Kidney Disease</i> , 1996, 3, 312-314.	2.2	12
538	Disturbed host defense in peritoneal cavity during CAPD: Characterization of responsible factors in dwell fluid. <i>Kidney International</i> , 1996, 50, 643-652.	2.6	24
539	Pathophysiology, Causes, and Prognosis of Acute Renal Failure in the Elderly. <i>Renal Failure</i> , 1996, 18, 333-346.	0.8	23
540	Mechanisms of uremic inhibition of phagocyte reactive species production: Characterization of the role of p-cresol. <i>Kidney International</i> , 1995, 47, 510-517.	2.6	139

#	ARTICLE	IF	CITATIONS
541	Middle Molecules: Toxicity and Removal by Hemodialysis and Related Strategies. <i>Artificial Organs</i> , 1995, 19, 1120-1125.	1.0	18
542	Recombinant hirudin: A specific thrombin inhibiting anticoagulant for hemodialysis. <i>Kidney International</i> , 1994, 45, 1754-1759.	2.6	62
543	Inhibition of nuclear uptake of calcitriol receptor by uremic ultrafiltrate. <i>Kidney International</i> , 1994, 46, 129-133.	2.6	29
544	The biological action of calcitriol in renal failure. <i>Kidney International</i> , 1994, 46, 605-612.	2.6	33
545	Influence of Erythropoietin on Dialyzer Reuse, Heparin Need, and Urea Kinetics in Maintenance Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 1994, 23, 52-59.	2.1	12
546	Middle Molecules as Uremic Toxins: Still a Viable Hypothesis?. <i>Seminars in Dialysis</i> , 1994, 7, 65-68.	0.7	8
547	Contributing factors to the inhibition of phagocytosis in hemodialyzed patients. <i>Kidney International</i> , 1993, 44, 208-214.	2.6	45
548	There Is Insufficient Evidence That Membrane Incompatibility Causes Amyloidosis. <i>Seminars in Dialysis</i> , 1993, 6, 189-192.	0.7	2
549	Pain at the Injection Site of Subcutaneously Administered Erythropoietin in Maintenance Hemodialysis Patients: A Comparison of Two Brands of Erythropoietin. <i>American Journal of Nephrology</i> , 1992, 12, 68-72.	1.4	30
550	A longitudinal, five year survey of urea kinetic parameters in CAPD patients. <i>Kidney International</i> , 1992, 42, 426-432.	2.6	179
551	Correction of Deficient Phagocytosis During Erythropoietin Treatment in Maintenance Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 1992, 19, 358-363.	2.1	50
552	Adequacy of dialysis: A critical analysis. <i>Kidney International</i> , 1992, 42, 540-558.	2.6	108
553	Radiochemical determination of twelve trace elements in human blood serum. <i>Analytica Chimica Acta</i> , 1992, 257, 1-5.	2.6	27
554	Should Cuprophane Membranes Continue to Be Used for Chronic Hemodialysis?. <i>Seminars in Dialysis</i> , 1992, 5, 118-120.	0.7	0
555	Subfractions in uremic plasma ultrafiltrate inhibit calcitriol metabolism. <i>Kidney International</i> , 1991, 40, 868-873.	2.6	44
556	Phagocytosis in uremic and hemodialysis patients: A prospective and cross sectional study. <i>Kidney International</i> , 1991, 39, 320-327.	2.6	190
557	A review of the pathophysiology, causes and prognosis of acute renal failure in the elderly. <i>Geriatric Nephrology and Urology</i> , 1991, 1, 77-91.	0.4	13
558	Intradialytic Body Weight Changes and Dialyzer Pore Size as Main Contributing Factors to the Evolution of Beta-2-Microglobulin in Dialysis. <i>Blood Purification</i> , 1990, 8, 32-44.	0.9	12

#	ARTICLE	IF	CITATIONS
559	Drug protein binding in chronic renal failure: Evaluation of nine drugs. <i>Kidney International</i> , 1988, 33, 996-1004.	2.6	142
560	How Should Temporary Vascular Access for Hemodialysis Be Achieved?. <i>Seminars in Dialysis</i> , 1988, 1, 190-191.	0.7	0
561	Influence of Reuse and of Reuse Sterilants on the First Use Syndrome. <i>Artificial Organs</i> , 1987, 11, 137-139.	1.0	13
562	Cuprophane reuse and intradialytic changes of lung diffusion capacity and blood gasses. <i>Kidney International</i> , 1987, 32, 117-122.	2.6	38
563	Membrane plasma exchange in patients with metastatic cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 1985, 110, 230-233.	1.2	0
564	Unipuncture Membrane Plasmapheresis. <i>Artificial Organs</i> , 1983, 7, 365-372.	1.0	3
565	Dissociation of glomerular filtration and renal blood flow in HgCl <sub>2</sub> -induced acute renal failure. <i>Kidney International</i> , 1982, 22, 162-170.	2.6	16
566	Diquat intoxication. <i>American Journal of Medicine</i> , 1981, 70, 1267-1271.	0.6	87
567	Primary Hodgkin's Disease of the Thyroid. <i>Acta Haematologica</i> , 1981, 65, 54-59.	0.7	5
568	Experience with Continuous Ambulatory Peritoneal Dialysis in Belgium. <i>Peritoneal Dialysis International</i> , 1980, 1, 54-58.	1.1	12
569	Selection of Peritoneal Dialysis as Renal Replacement Therapy. , 0, , 469-477.		0